Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $126.1 million.

  • Prestige Consumer Healthcare's Cost of Revenue fell 247.01% to $126.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $484.3 million, marking a year-over-year decrease of 351.58%. This contributed to the annual value of $503.3 million for FY2025, which is 47.71% up from last year.
  • As of Q4 2025, Prestige Consumer Healthcare's Cost of Revenue stood at $126.1 million, which was down 247.01% from $122.5 million recorded in Q3 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Cost of Revenue ranged from a high of $132.1 million in Q1 2023 and a low of $100.7 million during Q1 2021
  • Its 5-year average for Cost of Revenue is $121.6 million, with a median of $124.7 million in 2023.
  • As far as peak fluctuations go, Prestige Consumer Healthcare's Cost of Revenue surged by 1952.83% in 2021, and later plummeted by 984.23% in 2025.
  • Quarter analysis of 5 years shows Prestige Consumer Healthcare's Cost of Revenue stood at $119.4 million in 2021, then rose by 4.78% to $125.1 million in 2022, then decreased by 0.25% to $124.8 million in 2023, then grew by 3.58% to $129.3 million in 2024, then dropped by 2.47% to $126.1 million in 2025.
  • Its last three reported values are $126.1 million in Q4 2025, $122.5 million for Q3 2025, and $109.2 million during Q2 2025.